TITLE

Expression of thiopurine methyltransferase in South Asians

AUTHOR(S)
Tsironi, E.; Browne, M.; Rampton, D. S.; Ballinger, A. B.
PUB. DATE
June 2003
SOURCE
Gut;Jun2003, Vol. 52 Issue 6, p914
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66252102

 

Related Articles

  • CORRIGENDUM: Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing.  // Clinical Pharmacology & Therapeutics;Dec2011, Vol. 90 Issue 6, p894 

    A correction to the article "Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing" that was published in the 2011 issue is presented.

  • A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Yang, Suk-Kyun; Hong, Myunghee; Baek, Jiwon; Choi, Hyunchul; Zhao, Wanting; Jung, Yusun; Haritunians, Talin; Ye, Byong Duk; Kim, Kyung-Jo; Park, Sang Hyoung; Park, Soo-Kyung; Yang, Dong-Hoon; Dubinsky, Marla; Lee, Inchul; McGovern, Dermot P B; Liu, Jianjun; Song, Kyuyoung // Nature Genetics;Sep2014, Vol. 46 Issue 9, p1017 

    Thiopurine therapy, commonly used in autoimmune conditions, can be complicated by life-threatening leukopenia. This leukopenia is associated with genetic variation in TPMT (encoding thiopurine S-methyltransferase). Despite a lower frequency of TPMT mutations in Asians, the incidence of...

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update. Relling, M V; Gardner, E E; Sandborn, W J; Schmiegelow, K; Pui, C-H; Yee, S W; Stein, C M; Carrillo, M; Evans, W E; Hicks, J K; Schwab, M; Klein, T E // Clinical Pharmacology & Therapeutics;Apr2013, Vol. 93 Issue 4, p324 

    The article reviews the March 2011 issue of the periodical "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing."

  • Recent advances in the pharmacogenomics of thiopurine methyltransferase. Coulthard, S.A.; Hall, A.G. // Pharmacogenomics Journal;2001, Vol. 1 Issue 4, p254 

    Investigates the range of inter-individual variation that may be involved in the open reading frame or promoter region of the thiopurine methyltransferase (TPMT). Influence of the variations may have on both the clinical efficacy and toxicity of the thiopurine drugs; Overview of thiopurine...

  • Thiopurine methyltronsferase screening before azothioprine therapy. Gauba, Vinod; Saldanha, M.; Vize, C.; Saleh, G. M. // British Journal of Ophthalmology;Jul2006, Vol. 90 Issue 7, p923 

    A letter to the editor is presented in response to the article about thiopurine methyltransferase screening before azathioprine therapy in the previous issue.

  • TPMT in the treatment of Crohn's disease with azathioprine. Lennard, L. // Gut;Aug2002, Vol. 51 Issue 2, p143 

    Discusses the treatment of Crohn's disease with azathioprine. Association of thiopurine methyltransferase (TMPT) deficiency; Role of TMPT in the clinical pharmacology of thiopurine drugs; Drug-drug interactions; Disease background of TMPT.

  • Erratum to: Thiopurine S-Methyltransferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis. Hagaman, Jared T.; Kinder, Brent W.; Eckman, Mark H. // Lung;May2011, Vol. 189 Issue 3, p259 

    A correction to the article "Thiopurine S-Methyltransferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis" that was published in the 2010 issue is presented.

  • Azathioprine.  // Reactions Weekly;10/5/2013, Issue 1472, p9 

    An abstract of the article "Thiopurine methyltransferase measurement may not predict azathiopurine-associated non-myelotoxicity," by Q. Yao and colleagues is presented.

  • Azathioprine.  // Reactions Weekly;10/23/2010, Issue 1324, p13 

    The article describes the cases of four thiopurine methyltransferase (TPMT) heterozygous patients who developed various toxicities while undergoing azathioprine treatment.

  • Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients. Derijks, L. J. J.; Van Helden, R. B.; Hommes, D. W.; Stokkers, P. C. // Gut;Jun2008, Vol. 57 Issue 6, p872 

    A letter to the editor is presented in response to the article "Safe treatment of thiopurine S-methyltransferase (TPMT) deficient Crohn's disease patients with azathioprine (AZA)," by Kaskas and colleagues.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics